A novel decision aid was used in both encounters to disclose the CHD risk estimates and facilitate SDM regarding statin use. A genetic counselor disclosed this information followed by a physician visit for SDM regarding statin therapy. We randomized 207 patients, age 45– 65 years, at intermediate CHD risk, and not on statins, to receive the 10-year risk of CHD based on conventional risk factors alone (n=103) or in combination with a genetic risk score (n=104). Whether disclosure of genetic risk for coronary heart disease (CHD) influences shared decision-making (SDM) regarding use of statins to reduce CHD risk is unknown.
#Iftikhar kullo goggle scholar registration
Disclosure of CHD genetic risk using an electronic health record-linked decision aid did not adversely affect SDM or patients' satisfaction with the clinical encounter.Trial registration numberNCT01936675 Results.
Quantitative analyses of a random subset of 80 video-recorded encounters using the OPTION5 scale also showed no significant difference in SDM between the two groups. There were no statistically significant differences between the two groups in the SDM score, satisfaction with the clinical encounter, perception of the quality of the discussion or of participation in decision-making and physician visit satisfaction scores. Patients reported their decision quality and physician visit satisfaction using validated surveys. We randomized 207 patients, age 45-65 years, at intermediate CHD risk, and not on statins, to receive the 10-year risk of CHD based on conventional risk factors alone (n=103) or in combination with a genetic risk score (n=104).
0 kommentar(er)
